Balaji Amines Targets Sales Expansion Via New Products And Facility Utilization

Market snapshot: Balaji Amines is targeting long-term top-line expansion driven by ramped-up capacity across newly commercialized facilities and product additions. The company intends to scale monthly production of key specialty chemical intermediates such as Acetonitrile to align with rising end-user demand.

Data Snapshot

• Balaji Amines commissioned its upgraded Acetonitrile facility with an enhanced installed capacity of 1,440 tonnes per month in Solapur.
• Consolidated total revenue for Q2 FY27 reached ₹472 crore, expanding from ₹348 crore in Q2 FY26.
• Consolidated net profit for Q2 FY27 increased to ₹67 crore, compared with ₹37 crore in Q2 FY26.

What's Changed

• Consolidated quarterly revenue expanded to ₹472 crore in Q2 FY27 from ₹348 crore in Q2 FY26.
• Acetonitrile production capacity stands expanded to 1,440 tonnes per month following technology upgrades at Unit-III.

Key Takeaways

• Balaji Amines aims for revenue between ₹3,500 crore and ₹4,000 crore by FY28-29 (as stated in the source alert; not independently verified).
• Acetonitrile monthly output is targeted to reach 1,000 to 1,200 tonnes starting December based on market demand (as stated in the source alert; not independently verified).
• Substantial capital expansion across specialty chemical product lines underpins operating leverage potential.

SAHI Perspective

Balaji Amines is positioning its business to capture volume recovery across agrochemical and pharmaceutical active pharmaceutical ingredient (API) value chains. The commissioning of its upgraded Acetonitrile unit at 1,440 tonnes per month provides the structural backbone necessary to realize its long-term revenue targets as demand ramps up.

Market Implications

Increased domestic production capacity for Acetonitrile strengthens import substitution opportunities in India's specialty chemicals landscape. Operating at higher capacity utilization levels can lower unit overheads, potentially strengthening operating margins for aliphatic amine manufacturers.

Trading Signals

Market Bias: Bullish

Supported by robust Q2 FY27 consolidated revenue of ₹472 crore (vs ₹348 crore YoY) and expanded Acetonitrile capacity of 1,440 tonnes per month, operating leverage offers mid-term upside structural strength.

Overweight: Speciality Chemicals, Aliphatic Amines & Derivatives

Trigger Factors:

• Monthly Acetonitrile capacity utilization levels.
• Raw material acetic acid price fluctuations.
• Downstream demand recovery from pharmaceutical API and agrochemical sectors.

Time Horizon: Medium-term (3-12 months)

Industry Context

India's specialty chemical sector has undergone significant expansion in Acetonitrile and amine derivatives to meet expanding pharmaceutical and agrochemical manufacturing demands while reducing dependence on chemical imports.

Key Risks to Watch

• Volatility in key chemical feedstocks such as acetic acid and ammonia.
• Delay in demand recovery across downstream pharmaceutical and agrochemical client segments.

Recent Developments

Balaji Amines commissioned its upgraded Acetonitrile plant with an enhanced capacity of 1,440 tonnes per month on September 24, 2026. For Q2 FY27, the company delivered consolidated total revenue of ₹472 crore and net profit of ₹67 crore.

Closing Insight

As global and domestic demand stabilizes, Balaji Amines' strategy of combining debottlenecked specialty chemical capacity with disciplined cost structures remains central to achieving long-term top-line scale.

High Performance Trading with SAHI.